A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Method, MD, MPH, MBA
ImmunoGen, Inc.
Study Director - Ursula Matulonis, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
89 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal North Shore Hospital
St Leonards, New South Wales, Australia
- Icon Cancer Care
Auchenflower, Queensland, Australia
- Peninsula and South Eastern Haematology & Oncology Group
Frankston, Victoria, Australia
- St John of God Subiaco Hospital
Subiaco, Western Australia, Australia
- Cliniques Universitaires Saint Luc - Lnstitut Roi Albert Ii
Brussels, Brussels Capital, Belgium
- Centre Hopsitalier de L'Ardenne
Libramont, Luxembourg, Belgium
- Uz Gent
Ghent, Belgium
- Uz Leuven
Leuven, Belgium
- Chu Ucl Namur/site Sainte Elisabeth
Namur, Belgium
- Mhat "serdika"
Sofia, Bulgaria
- Všeobecná Fakultní Nemocnice V Praze
Prague, Prague, Czechia
- Universitätsmedizin Mannheim
Mannheim, Baden-Wurttemberg, Germany
- Umg Frauenklinik Robert-Koch-Str. 40
Göttingen, Lower Saxony, Germany
- Kem
Essen, Germany
- Mater Misericordiae University Hospital
Dublin, Leinster, Ireland
- St. James'S Hospital
Dublin, Leinster, Ireland
- Bon Secours Hospital
Cork, Munster, Ireland
- Cork University Hospital
Cork, Munster, Ireland
- University Hospital Waterford
Waterford, Munster, Ireland
- Beaumont Hospital
Dublin, Ireland
- Rambam Medical Center
Haifa, Israel
- Hadassah Ein Kerem Medical Center
Jerusalem, Israel
- Shaare Zedek Medical Center
Jerusalem, Israel
- Meir Medical Center
Kfar Saba, Israel
- Sheba Medical Center
Ramat Gan, Israel
- Kaplan Medical Center
Rehovot, Israel
- Ziv Medical Center
Safed, Israel
- Policlinico S. Orsola-Malpighi
Bologna, Italy
- Azienda Socio Santaria Territoriale Degli Spedali Civili Di Brescia
Brescia, Italy
- Istituto Oncologico Candiolo
Candiolo, Italy
- Ospedale Cannizzaro Di Catania
Catania, Italy
- Azienda Ospedaliera Ospedale Niguarda Ca'Granda
Milan, Italy
- Ieo Istituto Europeo Di Oncologia
Milan, Italy
- Fondazione Irccs Istituto Nazionale Dei Tumori
Naples, Italy
- Istituto Nazionale Tumori- G. Pascale
Naples, Italy
- Ospedale S.Maria Della Misericordia
Perugia, Italy
- Fondazione Policlinico Universitario A. Gemelli Irccs
Roma, Italy
- Specjalistyczna Przychodnia Lekarska Medicus
Chorzów, Silesian Voivodeship, Poland
- Mazurskim Centrum Onkologiiw Olsztynie
Olsztyn, Warmian-Masurian Voivodeship, Poland
- Instytut Centrum Zdrowia Matki Polki
Lodz, Łódź Voivodeship, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Jul 2020
- Primary completion
- 16 Nov 2021
- Completion
- 16 Nov 2022
- Last update posted
- 7 Aug 2024
- Registered enrollment
- 106
- Registry id
- NCT04296890
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.